Overview

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

Status:
Completed

Trial end date:
2017-10-03

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).

Phase:

Phase 2

Details

Lead Sponsor:

Regeneron Pharmaceuticals

Treatments:

Aflibercept
Endothelial Growth Factors